Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely

References

• Druker BJ Guilhot F O’Brien SG Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 2006 355 23 2408 2417 17151364
   PubMed Web of Science ®Google Scholar
• Branford S Yeung DT Ross DM Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML Blood 2013 121 19 3818 3824 23515925
   PubMed Web of Science ®Google Scholar
• Mahon FX Rea D Guilhot J Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 2010 11 11 1029 1035 20965785
   PubMed Web of Science ®Google Scholar
• Ross DM Branford S Seymour JF Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study Blood 2013 122 4 515 522 23704092
   PubMed Web of Science ®Google Scholar
• Melo JV Ross DM Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? Hematology Am Soc Hematol Educ Program Book 2011 136 142
   Google Scholar
• Ohyashiki K Katagiri S Tauchi T Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib Br J Haematol 2012 157 2 254 256 22077498
   PubMed Web of Science ®Google Scholar
• Takahashi N Kyo T Maeda Y Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia Haematologica 2012 97 6 903 906 22180435
   PubMed Web of Science ®Google Scholar
• Mizoguchi I Yoshimoto T Katagiri S Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib Cancer Sci 2013 104 9 1146 1153 23758044
   PubMed Web of Science ®Google Scholar
• Ng KP Hillmer AM Chuah CT A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer Nat Med 2012 18 4 521 528 22426421
   PubMed Web of Science ®Google Scholar
• Katagiri S Umezu T Ohyashiki JH Ohyashiki K The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients Br J Haematol 2013 160 2 269 271 23116058
   PubMed Web of Science ®Google Scholar
• Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004 116 2 281 297 14744438
   PubMed Web of Science ®Google Scholar
• He L Thomson JM Hemann MT A microRNA polycistron as a potential human oncogene Nature 2005 435 7043 828 833 15944707
   PubMed Web of Science ®Google Scholar
• Baltimore D Boldin MP O’Connell RM Rao DS Taganov KD MicroRNAs: new regulators of immune cell development and function Nature Immunol 2008 9 8 839 845 18645592
   PubMed Web of Science ®Google Scholar
• O’Connell RM Rao DS Chaudhuri AA Baltimore D Physiological and pathological roles for microRNAs in the immune system Nat Rev Immunol 2010 10 2 111 122 20098459
   PubMed Web of Science ®Google Scholar
• Yu Y Yang L Zhao M Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells Leukemia 2012 26 8 1752 1760 22395361
   PubMed Web of Science ®Google Scholar
• Venturini L Battmer K Castoldi M Expression of the miR-17–92 polycistron in chronic myeloid leukemia (CML) CD34+ cells Blood 2007 109 10 4399 4405 17284533
   PubMed Web of Science ®Google Scholar
• San Jose-Eneriz E Roman-Gomez J Jimenez-Velasco A MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations Mol Cancer 2009 8 69 19723306
   PubMed Web of Science ®Google Scholar
• Rokah OH Granot G Ovcharenko A Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells PLoS One 2012 7 4 e35501 22511990
   PubMed Web of Science ®Google Scholar
• Umezu T Ohyashiki K Ohyashiki JH Detection method for quantifying global DNA methylation by fluorescence correlation spectroscopy Anal Biochem 2011 415 2 145 150 21600184
   PubMed Web of Science ®Google Scholar
• Ohyashiki K Umezu T Yoshizawa S Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin’s lymphoma PLoS One 2011 6 2 e16408 21383985
   PubMed Web of Science ®Google Scholar
• Etienne G Dulucq S Nicolini FE Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy Haematologica 2014 99 3 458 464 24362549
   PubMed Web of Science ®Google Scholar
• Rousselot P Charbonnier A Cony-Makhoul P Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease J Clin Oncol 2014 32 5 424 430 24323036
   PubMed Web of Science ®Google Scholar
• Chen Y Song YX Wang ZN The microRNA-148/152 family: multi-faceted players Mol Cancer 2013 12 43 23683438
   PubMed Web of Science ®Google Scholar
• Kim HP Leonard WJ CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation J Exp Med 2007 204 7 1543 1551 17591856
   PubMed Web of Science ®Google Scholar
• Wang L Liu Y Beier UH Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity Blood 20132 121 18 3631 3639 23444399
   PubMed Web of Science ®Google Scholar
• Rea D Dulphy N Henry G Low Natural Killer (NK) Cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results rrom immunostim, on behalf of STIM investigators Blood 2013 122 21 Abstract #856
   Web of Science ®Google Scholar
• Larmonier N Janikashvili N LaCasse CJ Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors J Immunol 2008 181 10 6955 6963 18981115
   PubMed Web of Science ®Google Scholar
• Liu X Zhan Z Xu L MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIalpha J Immunol 2010 185 12 7244 7251 21068402
   PubMed Web of Science ®Google Scholar